Search results for "Amy"

showing 10 items of 1486 documents

Afferent and efferent projections of the anterior cortical amygdaloid nucleus in the mouse

2017

The anterior cortical amygdaloid nucleus (ACo) is a chemosensory area of the cortical amygdala that receives afferent projections from both the main and accessory olfactory bulbs. The role of this structure is unknown, partially due to a lack of knowledge of its connectivity. In this work, we describe the pattern of afferent and efferent projections of the ACo by using fluorogold and biotinylated dextranamines as retrograde and anterograde tracers, respectively. The results show that the ACo is reciprocally connected with the olfactory system and basal forebrain, as well as with the chemosensory and basomedial amygdala. In addition, it receives dense projections from the midline and posteri…

0301 basic medicineOlfactory systemBasal forebrainVomeronasal organLateral hypothalamusGeneral NeuroscienceEfferentThalamusAnatomyBiologyAmygdala03 medical and health sciencesStria terminalis030104 developmental biology0302 clinical medicinemedicine.anatomical_structurenervous systemmedicineNeuroscience030217 neurology & neurosurgeryJournal of Comparative Neurology
researchProduct

Afferent and Efferent Connections of the Cortex-Amygdala Transition Zone in Mice

2016

The transitional zone between the ventral part of the piriform cortex and the anterior cortical nucleus of the amygdala, named the cortex-amygdala transition zone (CxA), shows two differential features that allow its identification as a particular structure. First, it receives dense cholinergic and dopaminergic innervations as compared to the adjacent piriform cortex and amygdala, and second, it receives projections from the main and accessory olfactory bulbs. In this work we have studied the pattern of afferent and efferent projections of the CxA, which are mainly unknown, by using the retrograde tracer Fluorogold and the anterograde tracer biotinylated dextranamine. The results show that …

0301 basic medicineOlfactory systemVomeronasal organSistema nerviós central MalaltiesEfferentNeuroscience (miscellaneous)OlfactevomeronasalPiriform cortexAmygdala03 medical and health sciencesCellular and Molecular Neurosciencepiriform cortex0302 clinical medicineNeural tracingPiriform cortexCortex (anatomy)medicineOriginal ResearchOlfactory tubercleAnatomyamygdalaNeuroanatomiaAmygdalaolfactoryVentral tegmental areaNeuroanatomy030104 developmental biologymedicine.anatomical_structurenervous systemAnatomyneural tracingPsychologyVomeronasalNeuroscience030217 neurology & neurosurgerypsychological phenomena and processesOlfactoryFrontiers in Neuroanatomy
researchProduct

Identification of accessory olfactory system and medial amygdala in the zebrafish

2017

AbstractZebrafish larvae imprint on visual and olfactory cues of their kin on day 5 and 6 postfertilization, respectively. Only imprinted (but not non-imprinted) larvae show strongly activated crypt (and some microvillous) cells demonstrated by pERK levels after subsequent exposure to kin odor. Here, we investigate the olfactory bulb of zebrafish larvae for activated neurons located at the sole glomerulus mdG2 which receives crypt cell input. Imprinted larvae show a significantly increased activation of olfactory bulb cells compared to non-imprinted larvae after exposure to kin odor. Surprisingly, pERK activated Orthopedia-positive cell numbers in the intermediate ventral telencephalic nucl…

0301 basic medicineOlfactory systemanimal structuresGene ExpressionSensory systemImprinting PsychologicalAmygdalaArticleOlfactory Receptor Neurons03 medical and health sciences0302 clinical medicinemedicineAnimalsPhosphorylationZebrafishZebrafishFluorescent DyesGlomerulus (olfaction)Microscopy ConfocalMitogen-Activated Protein Kinase 3MultidisciplinarybiologyfungiOlfactory PathwaysCarbocyaninesZebrafish ProteinsAmygdalabiology.organism_classificationOlfactory BulbOlfactory bulbCell biologySmell030104 developmental biologymedicine.anatomical_structureOdorHypothalamusLarvaOdorants030217 neurology & neurosurgeryTranscription FactorsScientific Reports
researchProduct

Pregnancy Changes the Response of the Vomeronasal and Olfactory Systems to Pups in Mice

2020

Motherhood entails changes in behavior with increased motivation for pups, induced in part by pregnancy hormones acting upon the brain. This work explores whether this alters sensory processing of pup-derived chemosignals. To do so, we analyse the expression of immediate early genes (IEGs) in the vomeronasal organ (VNO; Egr1) and centers of the olfactory and vomeronasal brain pathways (cFos) in virgin and late-pregnant females exposed to pups, as compared to buttons (socially neutral control). In pup-exposed females, we quantified diverse behaviors including pup retrieval, sniffing, pup-directed attack, nest building and time in nest or on nest, as well as time off nest. Pups induce Egr1 ex…

0301 basic medicineOlfactory systemmedicine.medical_specialtymiceVomeronasal organSensory processingmedicine.medical_treatmentIEGsolfactory systemBiologyAmygdalalcsh:RC321-571vomeronasal system03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineSniffingPiriform cortexInternal medicinemedicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal ResearchAggressionpup chemosignalsStria terminalis030104 developmental biologyEndocrinologymedicine.anatomical_structureCellular Neurosciencesense organspregnancymedicine.symptom030217 neurology & neurosurgeryFrontiers in Cellular Neuroscience
researchProduct

Genetically elevated gamma-glutamyltransferase and Alzheimer's disease

2018

Observational epidemiological evidence supports a linear and independent association between serum gamma-glutamyltransferase (GGT) concentrations and the risk of Alzheimer's disease (AD). However, the causality of this association has not been previously investigated. We sought to assess the causal nature of this association using a Mendelian randomization (MR) approach. Using inverse-variance weighted MR analysis, we assessed the association between GGT and AD using summary statistics for single nucleotide polymorphism (SNP)-AD associations obtained from the International Genomics of Alzheimer's Project of 17,008 individuals with AD and 37,154 controls. We used 26 SNPs significantly associ…

0301 basic medicineOncologyAgingentsyymitDisease030204 cardiovascular system & hematologyAlzheimerin tautiBiochemistryGWAS genome-wide association studiestransferaasit0302 clinical medicineEndocrinologyEpidemiologyMedicineNHGRI National Human Genome Research InstituteGamma-glutamyltransferasebiologyMR Mendelian randomizationGenetic Pleiotropyta3142SNP single nucleotide polymorphismAlzheimer's disease3. Good healthEuropeAD Alzheimer's diseasegeneettiset tekijätmedicine.medical_specialtySingle-nucleotide polymorphismGRS genetic risk scoreta3111Polymorphism Single NucleotideArticle03 medical and health sciencesAlzheimer DiseaseInternal medicineMendelian randomizationGeneticsMendelian randomizationSNPHumansMolecular Biologybusiness.industryGGT gamma-glutamyltransferaseIGAP International Genomics of Alzheimer's ProjectGenetic VariationGamma-glutamyltransferaseCell BiologyOdds ratioMendelian Randomization AnalysisConfidence intervalCI confidence intervalOR odds ratio030104 developmental biologyCase-Control Studiesbiology.proteinbusinessSD standard deviationGenome-Wide Association StudyExperimental Gerontology
researchProduct

Compassionate use of everolimus for refractory epilepsy in a patient with MTOR mosaic mutation

2020

Abstract The MTOR gene encodes the mechanistic target of rapamycin (mTOR), which is a core component of the PI3K-AKT-mTOR signaling pathway. Postzygotic MTOR variants result in various mosaic phenotypes, referred to in OMIM as Smith-Kinsgmore syndrome or focal cortical dysplasia. We report here the case of a patient, with an MTOR mosaic gain-of-function variant (p.Glu2419Lys) in the DNA of 41% skin cells, who received compassionate off-label treatment with everolimus for refractory epilepsy. This 12-year-old-girl presented with psychomotor regression, intractable seizures, hypopigmentation along Blaschko's lines (hypomelanosis of Ito), asymmetric regional body overgrowth, and ocular anomali…

0301 basic medicineOncologyCompassionate Use Trialsmedicine.medical_specialty[SDV]Life Sciences [q-bio]030105 genetics & heredityMuscle hypertrophyCraniofacial Abnormalities03 medical and health sciencesInternal medicineGeneticsmedicineHumansEverolimusChildMechanistic target of rapamycinProtein Kinase InhibitorsGenetics (clinical)PI3K/AKT/mTOR pathwayHypopigmentationEverolimusbiologybusiness.industryMosaicismTOR Serine-Threonine KinasesNeuropsychologyGeneral MedicineCortical dysplasiamedicine.disease3. Good healthClinical trialMalformations of Cortical Development[SDV] Life Sciences [q-bio]030104 developmental biologyPhenotypeGain of Function Mutationbiology.proteinFemaleEpilepsies Partialmedicine.symptombusinessmedicine.drug
researchProduct

Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease.

2021

Background: Alzheimer’s disease (AD) is the most common form of dementia and biomarkers are essential to help in the diagnosis of this disease. Image techniques and cerebrospinal fluid (CSF) biomarkers are limited in their use because they are expensive or invasive. Thus, the search for blood-borne biomarkers is becoming central to the medical community. Objective: The main objective of this study is the evaluation of three serum proteins as potential biomarkers in AD patients. Methods: We recruited 27 healthy controls, 19 mild cognitive impairment patients, and 17 AD patients. Using the recent A/T/N classification we split our population into two groups (AD and control). We used ELISA kits…

0301 basic medicineOncologyMalemedicine.medical_specialtyPopulationDiseaseRAGE (receptor)03 medical and health scienceseIF-2 Kinase0302 clinical medicineCerebrospinal fluidAlzheimer DiseaseAntigens NeoplasmInternal medicinemedicineDementiaHumanseducationAgedAged 80 and overeducation.field_of_studyAmyloid beta-PeptidesClusterinbiologybusiness.industryGeneral NeuroscienceGeneral MedicineMiddle Agedmedicine.diseaseBlood proteinsProtein kinase RPsychiatry and Mental healthClinical Psychology030104 developmental biologyClusterinbiology.proteinFemaleGeriatrics and GerontologyMitogen-Activated Protein Kinasesbusiness030217 neurology & neurosurgeryBiomarkersJournal of Alzheimer's disease : JAD
researchProduct

Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients

2015

Abstract Background Several studies suggest that pathological changes in Alzheimer’s disease (AD) brain begin around 10–20 years before the onset of cognitive impairment. Biomarkers that can support early diagnosis and predict development of dementia would, therefore, be crucial for patient care and evaluation of drug efficacy. Although cerebrospinal fluid (CSF) levels of Aβ42, tau, and p-tau are well-established diagnostic biomarkers of AD, there is an urgent need to identify additional molecular alterations of neuronal function that can be evaluated at the systemic level. Objectives This study was focused on the analysis of oxidative stress-related modifications of the CSF proteome, from …

0301 basic medicineOncologyPathologyDiseasephysiology (medical)medicine.disease_causeProtein oxidationtau proteins0302 clinical medicineCerebrospinal fluidmiddle aged80 and overoxidative stresshumansAged 80 and overamyloid beta-peptidesredox proteomicsagedfemale030220 oncology & carcinogenesisBiomarker (medicine)Alzheimer's diseaseAlzheimer diseaseAPOEmedicine.medical_specialtyoxidation-reductionproteomeCSFmolecular sequence data03 medical and health sciencesmalecognitive dysfunctionInternal medicinemental disordersmedicineDementiabiochemistryprotein oxidationbusiness.industrypeptide fragmentscase-control studiesCase-control studybiomarkersmedicine.diseaseAPOE; biomarkers; CSF; extracellular chaperones; protein oxidation; redox proteomics; aged; aged 80 and over; Alzheimer disease; amino acid sequence; amyloid beta-peptides; apolipoproteins E; biomarkers; case-control studies; cognitive dysfunction; female; humans; male; middle aged; molecular sequence data; oxidation-reduction; oxidative stress; peptide fragments; proteome; tau proteins; biochemistry; physiology (medical)extracellular chaperonesamino acid sequence030104 developmental biologybusinessOxidative stressapolipoproteins E
researchProduct

Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial)

2017

IntroductionRecent studies suggest that endoplasmic reticulum stress may play a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS) through an altered regulation of the proteostasis, the cellular pathway-balancing protein synthesis and degradation. A key mechanism is thought to be the dephosphorylation of eIF2α, a factor involved in the initiation of protein translation. Guanabenz is an alpha-2-adrenergic receptor agonist safely used in past to treat mild hypertension and is now an orphan drug. A pharmacological action recently discovered is its ability to modulate the synthesis of proteins by the activation of translational factors preventing misfolded protein accumula…

0301 basic medicineOncologyPathologyamyotrophic lateral sclerosisamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; adrenergic alpha-2 receptor agonist s; age of onset; amyotrophic lateral sclerosis; disease progression; double-blind method; endoplasmic reticulum stress; guanabenz; humans; italy; medical futility; neuroprotective agents; proteostasis deficienciesamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Medicine (all)randomized clinical trial guanabenzHelsinki declaration0302 clinical medicineProtocolAdrenergic alpha-2 Receptor Agonists1506Amyotrophic lateral sclerosisAge of OnsetGuanabenzMedicine (all)amyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein responseNeurodegenerationamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response;amyotrophic lateral sclerosis; guanabenz; motor neurone disease; neuromuscular disease; randomized clinical trial; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis DeficienciesGeneral Medicineunfolded protein responseEndoplasmic Reticulum StressRiluzoleNeuroprotective AgentsNeurologyTolerabilityItalyDisease Progression1713GuanabenzMedical Futilitymedicine.drugmedicine.medical_specialtyamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies; Medicine (all)Neuroprotection03 medical and health sciencesmotor neurone diseaseDouble-Blind MethodInternal medicinemedicineHumansProteostasis Deficienciesbusiness.industryAmbientaleneuromuscular diseaserandomized clinical trialmedicine.diseaseClinical trial030104 developmental biologybusiness030217 neurology & neurosurgery
researchProduct

Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer’s Disease and Chronic Progressive Multiple Sclerosis: A Review

2020

Background: Reducing the burden of beta-amyloid accumulation and toxic autoimmunity-related proteins, one of the recognized pathophysiological markers of chronic and common neurological disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS), may be a valid alternative therapy to reduce their accumulation in the brain and thus reduce the progression of these disorders. The objective of this review was to evaluate the efficacy of plasmapheresis (PP) in AD and chronic progressive MS patients (in terms of improving clinical symptoms) and to analyze its safety and protocols. Methods: Articles related to this topic and published without time limitations in the Medline, and C…

0301 basic medicineOncologymedicine.medical_specialtyAmyloid betamedicine.medical_treatmentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441DiseaseReviewlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineVerbal fluency testDementiamagnetic resonance imagingauto-immunityalbuminbiologybusiness.industryMultiple sclerosislcsh:Rmedicine.diseasePathophysiologyamyloid beta030104 developmental biologyplasmapheresisToxicitybiology.proteinMolecular MedicinePlasmapheresisbusiness030217 neurology & neurosurgerydementiaPharmaceuticals
researchProduct